CRISPR Therapeutics AG (CRSP) vs MiniMed Group, Inc. Common Stock (MMED)
A side-by-side comparison of CRISPR Therapeutics AG and MiniMed Group, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$54.14HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
MMED
MiniMed Group, Inc. Common Stock
$19.65HealthcareDelayed quote: Oct 6, 2026, 1:25 PM EDT
Total return — CRSP vs MMED
growth of $100 · dividends reinvested · last 1yCRSP +0.0% (+0.0%/yr)MMED +9.0% (+9.0%/yr)MMED compounded faster over this window
CRSP MMED
CRSP vs MMED: by the numbers
- •MMED is the larger company ($5.52B vs $5.22B market cap).
- •Both run net losses; MMED's is the smaller (-10.21% vs -3368.72% net margin).
Metrics side by side
Valuation
| Metric | CRSP | MMED |
|---|---|---|
| Forward P/E | N/A | 29.18 |
| P/S ratio | 389.91 | 1.71 |
| P/B ratio | 2.99 | 1.52 |
| EV / EBITDA | N/A | 30.69 |
Profitability
| Metric | CRSP | MMED |
|---|---|---|
| Gross margin | -6537.01% | 53.85% |
| Operating margin | -16191.40% | 0.53% |
| Net margin | -3368.72% | -10.21% |
| ROE | -25.83% | -9.09% |
| ROIC | -21.12% | 0.43% |
Growth (annualized)
| Metric | CRSP | MMED |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | N/A |
| Total return CAGR (5Y) | -10.97% | N/A |
Go deeper
Dig into the metrics
CRISPR Therapeutics AG ROEMiniMed Group, Inc. Common Stock ROECRISPR Therapeutics AG operating marginMiniMed Group, Inc. Common Stock operating marginCRISPR Therapeutics AG revenue growthMiniMed Group, Inc. Common Stock revenue growthCRISPR Therapeutics AG free cash flowMiniMed Group, Inc. Common Stock free cash flow
CRISPR Therapeutics AG & MiniMed Group, Inc. Common Stock appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.